Clozapine

Clozapine (brand name Clozaril) is an atypical antipsychotic medication approved by the FDA for use in patients with treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in individuals with schizophrenia or schizoaffective disorder.

This drug is primarily indicated when patients have not responded adequately to standard antipsychotic treatments. It has unique efficacy in reducing psychotic symptoms and lowering suicide risk.

Clozapine antagonizes dopamine D2 and serotonin 5-HT2A receptors. The receptor profile is broader than older antipsychotics, which is part of why it remains effective in patients who haven't responded to other drugs.

One of the primary genes involved in clozapine metabolism is CYP2D6, a member of the cytochrome P450 enzyme family. CYP2D6 helps convert clozapine into its active and inactive metabolites that the body can eliminate.

Alterations in CYP2D6 activity, due to inherited genetic variants, can change how quickly clozapine is broken down. Individuals with high-activity variants may clear the drug too rapidly, while those with low-activity variants may accumulate higher levels, affecting both efficacy and the risk of side effects.

CYP2D6 phenotype classifications—ultrarapid, normal, intermediate, and poor metabolizers—directly influence clozapine plasma concentrations. Ultrarapid metabolizers may experience reduced drug exposure and subtherapeutic effects, while poor metabolizers can have elevated levels, increasing the likelihood of adverse reactions.

Ultrarapid Metabolizer

• Effect on drug levels: Lower than expected clozapine concentrations.
• Clinical consequence: Potential reduced efficacy and risk of symptom relapse.
• Side effects: Generally fewer dose‐related side effects; incomplete symptom control may occur.

Normal Metabolizer

• Effect on drug levels: Expected therapeutic concentrations.
• Clinical consequence: Standard efficacy and tolerability.
• Side effects: Typical side effects such as sedation and hypersalivation; usually mild to moderate.

Intermediate Metabolizer

• Effect on drug levels: Moderately elevated clozapine concentrations.
• Clinical consequence: Slightly enhanced efficacy; mild increase in adverse effects.
• Side effects: Mild sedation and dose‐related side effects may be more pronounced.

Poor Metabolizer

• Effect on drug levels: Significantly higher clozapine concentrations.
• Clinical consequence: Increased risk of adverse effects at standard doses.
• Side effects: Higher incidence of sedation, seizures, and hypotension; severity may be moderate to severe.

Indeterminate/Not available

• Effect: Unknown.
• Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
• Side effects: Unknown; monitor patient response closely.

CYP2D6 Dosing Guideline

Examples from guidelines include alternative atypical antipsychotics such as risperidone or olanzapine. These should be considered based on patient-specific factors and clinical judgment; this is not medical advice.

• FDA – Table of Pharmacogenetic Associations